Abstracts tagged "Compliance"

Abstract Number: 78 • 2014 ACR/ARHP Annual Meeting
a HPLC-SRM-MS Based Method for the Detection and Quantification of Methotrexate Used at Doses in Clinical Practice for Patients with Rheumatological Disease in Urine
James Bluett¹, Isabel Riba-Garcia², Richard Unwin², Suzanne Verstappen³ and Anne Barton^4,5, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom
Background/Purpose Methotrexate (MTX) is a recommended first-line therapy in 2013 EULAR guidelines for active rheumatoid arthritis (RA). Despite this, up to 54% do not adequately…
Abstract Number: 2399 • 2014 ACR/ARHP Annual Meeting
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Gerolamo Bianchi¹, Antonio Carletto², Oscar Massimiliano Epis³, Crescenzio Scioscia⁴, Angelo Semeraro⁵, Laura Bianchino⁶, Laura Bazzichi⁷, Giovanni Lapadula⁸, Luigi Sinigaglia⁹ and Andrea Lo Monaco¹⁰, ¹Div Reumatologia, ASL3 Genovese, Genoa, Italy, ²Dipartimento di Medicina,U.O. Complessa di Reumatologia ,Azienda Ospedaliera Universitaria di Verona, Verona, Italy, ³Rheumatology Unit, Niguarda Ca' Granda Hospital, Milan, Italy, ⁴University of Bari, Bari, Italy, ⁵P.O. “Valle d'Itria, Martina Franca, Italy, ⁶Roche Spa., Monza, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy, ⁸DIM, Rheumatology Unit, Bari, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Medical Sciences-Rheumatology Unit, Azienda ospedaliero-universitaria Sant'Anna, Ferrara, Italy
Background/Purpose Approximately 50% of patients (pts) with chronic diseases are non-adherent to the therapeutic regimen assigned. In pts with rheumatoid arthritis (RA), the non-adherence to…
Abstract Number: 2373 • 2014 ACR/ARHP Annual Meeting
Compliance in the Rheumatoid Arthritis Comparison of Active Therapies Trial: Triple Vs Etanercept
Sarah Leatherman¹, Hongsheng Wu^2,3, Edward Keystone⁴, Mary Brophy¹ and James O'Dell^5,6, ¹MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³Computer Science and Systems, Wentworth Institute of Technology, Boston, MA, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵VA Nebraska-Western Iowa Health Care System, Omaha, NE, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose In the 48-week, double-blinded, noninferiority RACAT trial, 353 methotrexate suboptimal responders were randomized to two treatment strategies, either the addition of sulfasalazine and hydroxychloroquine…
Abstract Number: 2382 • 2014 ACR/ARHP Annual Meeting
Adherence to Dmards in the First Six Months of Treatment in Early Arthritis Patients; Comparing Three Adherence Measures
Annelieke Pasma¹, Ethan den Boer², Adriaan van 't Spijker³, Reinier Timman³, Jan van Busschbach³ and J.M.W. Hazes⁴, ¹Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose Non-adherence to DMARDs is an important indicator for the effectiveness of treatment in early arthritis patients. Reported non-adherence rates differ widely, because studies use…
Abstract Number: 2368 • 2014 ACR/ARHP Annual Meeting
Impact of Physicians’ Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis
Laura Kuusalo¹, Kari Puolakka², Hannu Kautiainen³, Marjatta Leirisalo-Repo⁴ and Vappu Rantalaiho⁵, ¹Department of Internal Medicine, Division of Rheumatology, Turku University Hospital, Turku, Finland, ²Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Medcare Oy, Äänekoski, Finland, ⁴Department of Medicine, Division Of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Department of Internal Medicine, Centre for Rheumatic Diseases,, Tampere University Hospital, Tampere, Finland
Background/Purpose We have previously shown that in early rheumatoid arthritis (RA) remission targeted, intensive combination treatment, regardless of initial infliximab, results in remission in most…
Abstract Number: 2306 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^2,3,4, Eric C. Sayre³, Michal Abrahamowicz⁵, John M. Esdaile^2,6,7 and Diane Lacaille^8,9,10, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of decreased quality of life, and increased mortality in RA. RA is associated with an increased risk…
Abstract Number: 2308 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^3,4,5, Eric C. Sayre⁴, Michal Abrahamowicz⁶, John M. Esdaile^3,7,8 and Diane Lacaille^9,10,11, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Richmond, BC, Canada, ³Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ⁴Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁶Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰Arthritis Research Centre of Canada, Vancouver, BC, Canada, ¹¹University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of reduced quality of life and increased mortality in RA. Cardiovascular diseases are the leading cause of…
Abstract Number: 2107 • 2014 ACR/ARHP Annual Meeting
Characterization of Social Stigma in Rheumatic Diseases and Correlation with Quality of Life and Medication Adherence
Gihyun Myung^1,2, Nancy D. Harada^3,4, Stephanie L. Fong¹, Cleopatra Aquino-Beaton^1,5 and Meika A Fang⁶, ¹VA Greater Los Angeles Healthcare System, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Long Beach, CA, ⁴VA Office of Academic Affiliations, Long Beach, CA, ⁵UCLA School of Nursing, Los Angeles, CA, ⁶Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA
Background/Purpose Patients with rheumatoid arthritis and other rheumatic conditions may have physical deformities and functional limitations which make them vulnerable to health-related stigma. The objectives…
Abstract Number: 2032 • 2014 ACR/ARHP Annual Meeting
Psychological Factors Predict Adherence to Methotrexate (MTX) in Rheumatoid Arthritis (RA); Findings from a Systematic Review of Rates, Predictors and Associations with Patient Outcomes
Holly Hope¹, James Bluett^1,2, Kimme Hyrich³, Lis Cordingley⁴ and Suzanne M. Verstappen³, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is a first line therapy for Rheumatoid Arthritis (RA). Treatment response to MTX is not universal, and nonadherence may partially explain poor…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
Abstract Number: 2829 • 2013 ACR/ARHP Annual Meeting
Statin Adherence and Risk Of Mortality In Patients With Rheumatoid Arthritis: A Population-Based Study
Mary De Vera^1,2, Michal Abrahamowicz³ and Diane Lacaille⁴, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Poor adherence with statin therapy is associated with increased mortality in the general population, but no corresponding data are available among patients with rheumatoid…
Abstract Number: 1908 • 2013 ACR/ARHP Annual Meeting
Quality Of Life and Adherence To Treatment In Patients Managed In Nursing Clinics In Rheumatology
Santiago Muñoz-Fernández¹, Pablo Lazaro², Antonio Javier Blasco³, Sandra Fortea Gracia⁴, Laura Cano-García⁵, Jose A. Roman Ivorra⁶, Raquel Almodóvar González⁷, José Santos Rey Rey⁸, Teresa Navío-Marco⁹ and Mercedes Cabañas³, ¹Rheumatology, Hospital Infanta Sofía. San Sebastián de los Reyes. Spain, Madrid, Spain, ²Research, Advanced Techniques in Health Services Research (TAISS), Madrid, Spain, ³Advanced Techniques in Health Services Research (TAISS), Madrid, Spain, ⁴Servicio de Reumatología, Hospital de Sagunto, Sagunto, Spain, ⁵Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁶Servicio de ReumatologIa, Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁷Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁸Servicio de Reumatología, Complejo Hospitalario de Toledo, Toledo, Spain, ⁹Department of Rheumatology, Hospital Universitario Infanta Leonor, Madrid, Spain
Background/Purpose: Nursing clinics in rheumatology (NCR) are organizational models in the field of nursing care. However, little is known about the NCR outcomes. The purpose…
Abstract Number: 1243 • 2013 ACR/ARHP Annual Meeting
Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting
Amy H. Warriner¹, Ryan C. Outman², Allison Wyman³, Fred H. Hooven⁴, Jonathan D. Adachi⁵, Roland Chapurlat⁶, Juliet E. Compston⁷, Cyrus Cooper⁸, Jeffrey R. Curtis⁹, Adolfo Díez-Pérez¹⁰, Robert Lindsay¹¹, Lyn March¹², Jeri W. Nieves¹¹ and Kenneth G. Saag¹³, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Center for Outcomes Research, Center for Outcomes Research, UMass Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵McMaster University, Hamilton, ON, Canada, ⁶Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France, ⁷University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Internal Medicine, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, ¹¹Helen Hayes, West Haverstraw, NY, ¹²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹³Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medication adherence with prescription osteoporosis medications is poor, with approximately half remaining adherent in the first year of treatment. Moreover, approximately one-third who are…
Abstract Number: 1247 • 2013 ACR/ARHP Annual Meeting
Association Between Bisphosphonate Switching Behavior and Cost Outcomes In Postmenopausal United States Veterans
Joanne Lafleur¹, Scott L. DuVall², Jeffrey R. Curtis³, Robert A Adler⁴, Tina Willson⁵, Irene Agodoa⁶, Bradley Stolshek⁷ and Richard E. Nelson⁸, ¹University of Utah College of Pharmacy, Salt Lake City, UT, ²VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁵Pharmacotherapy, University of Utah, Salt Lake City, UT, ⁶Amgen Inc, Thousand Oaks, CA, ⁷Amgen, Inc., Thousand Oaks, CA, ⁸Division of Epidemiology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Many bisphosphonate-treated patients discontinue therapy within the first year. Some later restart the same or a different bisphosphonate. The implications of this on total…
Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].